nPharmakon has initiated several high potential R&D programs. The leading compound in each program is a clinically safe non-US drug, discovered using nPharmakon's drug retargeting technology to be active against a high value molecular target not addressed by existing therapies.

The programs available for partnering include:

NPH29 - for skin hyper-pigmentation disorders, including melasma and age spots, and skin lightening. Potential first-in-class. Proof-of-concept achieved in a clinical pilot.

NPH12 - for atopic dermatitis. Potential first-in-class.

NPH40 - for hepatocellular carcinoma. Potential first-in-class.